Remo MV (Remogliflozin+Vildagliptin+Metformin) combo for Type-2 Diabetes launch in India

October 26, 2021

Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected, globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2 diabetes).

Glenmark’s FDC of Remogliflozin + Vildagliptin + Metformin tackles most of the pathophysiology in Type 2 Diabetes that makes it an appealing fixed dose combination in managing uncontrolled Type 2 Diabetes. Mono components of the FDC are recommended by AACE guideline for early use in the hierarchy of Anti diabetic medications for management of Type 2 diabetes. Further, FDC of SGLT2i + DPP4i + Metformin is currently first & only triple drug FDC considered rational for approval by US FDA.

Glenmark has launched the same under two brand names Remo MV and Remozen MV.

Glenmark’s Remo MV and Remozen MV are priced at Rs16.5 per tab, Rs33 per day cost of therapy which is 53% lower than the other available SGLT2 & DPP4 combination brands administered along with Metformin, in India.

This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients.

Globally, SGLT2 inhibitors & DPP4 inhibitors are emerging as the preferred treatment option for the management of Type 2 diabetes. Glenmark has been at the forefront in providing access to the latest treatments at a low cost for patients with diabetes in India.

SOURCE

https://www.indiainfoline.com/article/news-sector-pharma-healthcare/glenmark-launches-remogliflozin-vildagliptin-metformin-combo-for-type-2-diabetes-in-india-121102600095_1.html